Orris

What is the discussion mostly comes in tah

Your message seems incomplete or garbled - I'm not sure what "tah" refers to or what discussion you mean. Could you clarify?
Asking for Preferences

Total abdominal hysterectomy

Your message seems incomplete or garbled - I'm not sure what "tah" refers to or what discussion you mean. Could you clarify?
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I have enough textbook detail to give a solid overview. Let me also check indications/complications sections quickly to round it out.
Finding Sources
Reading File
Reading File
Searching PubMed

"abdominal hysterectomy" AND complications

These confirm current textbook guidance is consistent with recent literature (route selection - vaginal/laparoscopic preferred over abdominal when feasible - remains supported by 2024-2026 systematic reviews).
Now I'll give the full answer.

Total Abdominal Hysterectomy (TAH)

Definition: TAH is the surgical removal of the uterine corpus and cervix through an open abdominal incision (as opposed to vaginal or minimally invasive/laparoscopic routes). The fallopian tubes and ovaries may or may not be removed concurrently (with salpingectomy/salpingo-oophorectomy).

Route selection

Per Berek & Novak's Gynecology, vaginal hysterectomy is generally the procedure of choice when feasible, with fewer perioperative complications than abdominal or laparoscopic routes. Abdominal hysterectomy is chosen when vaginal access is limited, uterine size is large, extensive adhesions/pathology exist, or malignancy requires wider exploration - Berek & Novak's Gynecology, p. 1408.

Preoperative preparation

  • Surgical site infection occurs in ~2% of hysterectomies; risk is raised by obesity, diabetes, smoking, steroid use, poor nutrition, and prior surgery.
  • Preoperative chlorhexidine bathing, chlorhexidine-alcohol skin prep, and a single dose of prophylactic cefazolin (1-2 g, 3 g if obese) 30-60 minutes before incision are recommended, with redosing after 3 hours or excessive bleeding.
  • Patient positioned supine, Foley catheter placed, vagina prepped with antiseptic.
  • Berek & Novak's Gynecology, p. 1419-1420.

Surgical steps

  1. Incision - low transverse or vertical midline, chosen based on indication, body habitus, prior scars, and need for exposure.
  2. Abdominal exploration - systematic palpation of liver, gallbladder, bowel, kidneys, and para-aortic nodes; peritoneal cytology if indicated.
  3. Retractor placement (Balfour, O'Connor-O'Sullivan, or Bookwalter) and uterine elevation via broad ligament clamps at the cornua.
  4. Round ligament transection - ligated or cauterized, opening the anterior leaf of the broad ligament along the vesicouterine fold to develop the bladder flap.
  5. Ureter identification - traced retroperitoneally along the medial leaf of the broad ligament, kept attached to preserve its blood supply.
  6. Adnexal management - if ovaries preserved, utero-ovarian ligaments are clamped, cut, and ligated; if removed, the infundibulopelvic ligament (ovarian vessels) is doubly clamped and ligated after confirming ureter location.
  7. Bladder mobilization - dissected off the lower uterine segment/cervix along the avascular plane.
  8. Uterine vessel ligation - uterine arteries skeletonized and clamped at the level of the internal cervical os, then suture-ligated.
  9. Cardinal and uterosacral ligament division - serially clamped, cut, and ligated after the bladder is dissected clear of the cervix.
  10. Vaginal incision and specimen removal, followed by vaginal cuff closure.
(Sabiston Textbook of Surgery, p. 2799-2800; Berek & Novak's Gynecology, p. 1420-1424)

Complications

Intraoperative: hemorrhage, and injury to the ureter, bladder, or bowel - similar risk profile to laparoscopic hysterectomy. Postoperative: incisional pain/infection, hemorrhage, urinary retention, ureteral injury, vesicovaginal fistula, vaginal cuff dehiscence, and (rarely) prolapse of the fallopian tube through the cuff.
  • Berek & Novak's Gynecology, p. 1408.

Common indications

Benign disease (fibroids, abnormal uterine bleeding unresponsive to conservative therapy, endometriosis with hysterectomy indicated), gynecologic malignancy (endometrial, cervical, uterine leiomyosarcoma - often with bilateral salpingo-oophorectomy and staging), obstetric emergencies (uncontrollable hemorrhage, uterine rupture, placenta accreta), and pelvic abscess unresponsive to medical therapy.
Recent (2024-2026) systematic reviews continue to support minimally invasive routes over open abdominal hysterectomy when technically feasible, citing lower complication rates, though abdominal approach remains standard for large uteri, malignancy staging, or when minimally invasive access is contraindicated (PMIDs: 38743951, 41259843, 40316173).
Would you like a diagram of the pelvic anatomy/surgical steps, or more detail on a specific aspect (e.g., indications, anesthesia considerations, or postoperative care)?

Endometrial thickness

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Searching PubMed

endometrial thickness cutoff race disparity endometrial cancer

I have solid textbook and current literature coverage. Here's the summary.

Endometrial Thickness

What it is: Endometrial thickness (the "endometrial stripe") is measured by transvaginal ultrasound and is a key screening parameter for endometrial pathology, especially in evaluating abnormal uterine bleeding (AUB) and postmenopausal bleeding.

Normal variation

  • Endometrial thickness varies substantially across the menstrual cycle in premenopausal women (thinnest just after menses, thickest in the secretory phase), which makes an isolated measurement far less diagnostically useful than in postmenopausal women - Berek & Novak's Gynecology, p. 444.
  • In postmenopausal women, the endometrium is normally thin (atrophic) due to low estrogen, so a thickened stripe is a more meaningful red flag.

Diagnostic thresholds (postmenopausal bleeding)

  • ≤4 mm: widely used cutoff below which endometrial biopsy may be deferred, as this correlates with low risk of malignancy - Sabiston Textbook of Surgery, p. 2795; Berek & Novak's Gynecology, p. 480.
  • <5 mm: some sources use this as the "unlikely to be cancer" threshold, with a few authors advocating a stricter 3 mm cutoff since diagnostic accuracy of the 4-5 mm rule may be overestimated - Berek & Novak's Gynecology, p. 481.
  • >4-5 mm, a polypoid mass, or intrauterine fluid collection on ultrasound: warrants further evaluation (endometrial biopsy, hysteroscopy, or sonohysterography) - Berek & Novak's Gynecology, p. 480.
  • The Washington Manual similarly notes biopsy may be avoided if thickness is <4 mm in the absence of recurrent bleeding.

Important recent caveat - racial disparity

Sabiston explicitly flags that the standard 4 mm cutoff underdiagnoses endometrial cancer in Black patients - a finding also supported by current literature. This matters because Black women tend to present with more aggressive, non-endometrioid histologic subtypes that don't always produce the classic thickened stripe, so a "reassuring" thin endometrium should not fully rule out biopsy if clinical suspicion remains.
  • Doll KM et al., "Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals," JAMA Oncology 2024 (PMID: 38935372) - found that thickness-based triage misses a meaningfully higher proportion of cancers in Black patients, supporting a lower threshold for biopsy regardless of ultrasound findings in this population.
  • Related reviews: PMID 38382150 (racial disparities in endometrial cancer, 2024), PMID 37902961 (health disparities in endometrial cancer care, 2024).

Clinical context

  • Endometrial thickness assessment sits within the broader postmenopausal bleeding workup: pelvic exam, Pap test, transvaginal ultrasound +/- sonohysterography, and endometrial sampling (office biopsy, hysteroscopy, or D&C) when indicated.
  • About 90% of endometrial cancer patients present with postmenopausal bleeding, and roughly 10% of women with postmenopausal bleeding overall are found to have a malignancy (endometrial or cervical) - Sabiston Textbook of Surgery, p. 2795.
  • Endometrial biopsy is also indicated regardless of thickness for: suspected focal lesion on imaging, difficulty visualizing the endometrium, or persistent bleeding despite a "normal" ultrasound.
If you want, I can pull the specific ultrasound criteria used in ACOG/SGO guidelines, or look at how endometrial thickness is used in fertility/IVF contexts (a different clinical use case) instead of the cancer-screening angle above.

17mm

17mm endometrial thickness has very different implications depending on context. Let me clarify before I dig into the textbooks.
Asking for Preferences
Finding Sources
Finding Sources
Reading File

17mm Endometrial Thickness - Premenopausal, with Abnormal Bleeding

Is this abnormal? Unlike postmenopausal women (clear-cut ≤4-5mm cutoff), there is no single universal numeric threshold for premenopausal women because thickness normally varies across the menstrual cycle - Berek & Novak's Gynecology notes that stripe measurements are "significantly less useful" in premenopausal women for this reason (p. 444).
Typical reference ranges across the cycle (general gynecologic knowledge, values vary by lab/source):
  • Early proliferative (post-menses): ~4-8 mm
  • Late proliferative/periovulatory: ~6-10 mm
  • Secretory phase (post-ovulation, highest point): up to ~14-16 mm
17mm sits at or above the upper limit even for the thickest normal phase (late secretory). Combined with abnormal uterine bleeding, this is clinically significant and not just attributable to normal cyclical variation.

What drives the concern at this thickness

Per Bailey and Love's Short Practice of Surgery, endometrial biopsy is indicated in premenopausal women when there is a persistently thickened or abnormal-appearing endometrium on ultrasound - p. relevant section, "Indications for an endometrial biopsy." A notably thicker cutoff of >7mm applies specifically to women with PCOS, because chronic unopposed estrogen (anovulation) predisposes to endometrial hyperplasia and, over time, carcinoma.

Likely causes of a thick premenopausal endometrium with AUB

  • Endometrial polyp - focal thickening, common benign cause
  • Endometrial hyperplasia - from unopposed estrogen (anovulation/PCOS, obesity, chronic estrogen exposure)
  • Submucosal fibroid - can mimic or add to stripe thickness on 2D ultrasound
  • Retained products of conception / early pregnancy - always exclude with a pregnancy test first
  • Adenomyosis - can distort measurement
  • Less commonly, endometrial carcinoma - the key "must not miss" diagnosis, particularly if risk factors exist (obesity, PCOS, unopposed estrogen, family history of endometrial/colon cancer, Lynch syndrome)

Recommended next steps (per textbook workup for AUB)

  1. Pregnancy test first, always, in a premenopausal woman.
  2. Sonohysterography to distinguish a focal lesion (polyp/fibroid) from diffuse thickening (hyperplasia).
  3. Endometrial biopsy (office aspiration, or hysteroscopy with directed biopsy if a focal lesion is suspected) - hysteroscopy with targeted biopsy is more sensitive than blind biopsy or D&C for focal pathology (Berek & Novak's Gynecology, p. 445).
  4. Standard AUB labs: CBC, thyroid function, prolactin, coagulation screen if indicated (Sabiston Textbook of Surgery, p. 2795).
This should not be interpreted as a diagnosis - a biopsy or hysteroscopy is the only way to distinguish benign causes (polyp, hyperplasia without atypia) from atypical hyperplasia or malignancy. If you can share the patient's age, BMI, PCOS status, or timing in the cycle, I can narrow down the likely differential further.
This is a shared conversation. Sign in to Orris to start your own chat.